Leor Sapir: The Questions the New York Times Refused to Ask (#27)
Leor Sapir dissects the New York Times' six-episode 'Protocol' series on youth transition, exposing how the paper spent two years on the subject while systematically avoiding its most basic question: what is gender identity? For European listeners navigating a rapidly shifting policy landscape, and for clinicians still anchoring practice to WPATH guidance, the critique lands close to home.
Leor Sapir is a fellow at the Manhattan Institute whose work has concentrated on the research base and institutional frameworks underpinning paediatric gender medicine. In this episode he offers a detailed analysis of the New York Times' six-part audio series 'The Protocol,' which the paper spent roughly two years producing. His verdict is blunt: a publication capable of sophisticated long-form investigation managed to circle the subject of youth transition without ever landing on its most foundational question — what, precisely, is gender identity? The critique matters well beyond American media criticism. Across continental Europe, journalists in Sweden, Germany, the Netherlands and France have faced versions of the same editorial pressure Sapir describes: a tendency to treat affirmative-care guidelines as a reasonable centre point while dismissing critical voices as fringe or ideologically motivated. The NYT's approach, Sapir argues, was not neutral but strategic — positioning unscientific assessment tools as the 'moderate middle ground' while lending institutional legitimacy to practices that several European health authorities have now restricted or paused pending further evidence. One of the episode's most striking passages concerns Laura Edwards-Leeper, a prominent American clinician long associated with a more cautious approach to paediatric transition. Sapir recounts that in his own interview with her, she acknowledged that gender identity as a clinical construct rests on stereotypes — an admission that, had it surfaced in the NYT series, would have reshaped the entire framing. European clinicians who still reference WPATH standards as their benchmark will recognise the circularity he describes: endocrinologists treating a condition defined only by the patient's own report of it, with no independent biological or psychological marker by which to verify or challenge that report. The episode also examines how the series handled detransitioners — people who have reversed a medical transition, often after lasting physical harm. Sapir notes they were granted seconds of airtime while a whistleblower who faced serious professional consequences received sustained critical scrutiny. This asymmetry will feel familiar to European audiences. In countries where detransitioner testimony has begun to surface in parliamentary hearings, clinical reviews and legal proceedings, the instinct to minimise such accounts has been a persistent obstacle to honest public debate. Sapir closes with a strategic observation that European policymakers and professional bodies would do well to weigh. As scrutiny intensifies — through systematic reviews, Nordic policy reversals and growing political pressure — medical institutions face a choice: acknowledge that guidelines from bodies like WPATH were inadequately evidenced, or wait for external investigation to make that case for them. The same fork is visible in European capitals. Whether professional societies in Germany, the Netherlands or at EU level opt for transparency or defensive solidarity may well determine how this chapter in medical history is eventually written.
